04-07-2006: ChemDiv, Inc. and Nerviano Medical Sciences (NervianoMS), Milano, Italy, announced an extension of their collaboration to an additional 2 year program. NervianoMS will use services of ChemDiv for building and enriching its portfolio of proprietary discovery chemical libraries. Such compound libraries are instrumental in enhancing the access to novel bioactive compounds.
This agreement capitalizes on ChemDiv´s success in contributing its world largest small molecule collection and library designs set to NervianoMS discovery chemistry assets, as well as strengths and experience in managing global medicinal and synthetic chemistry collaborations. NervianoMS has also entrusted ChemDiv with supporting NervianoMS inventory with global logistic services. Financial terms were not disclosed.
"Our business relationship with ChemDiv is entering a phase of joint scientific endeavours with ambitious goals of innovation. The strengths of High-Throughput Screening and Combinatorial Chemistry at NervianoMS shall be complemented with ChemDiv's fully aligned synthetic productivity. NervianoMS is a world leader in oncology-focused R&D and one of a handful that performs HTS with a throughput of millions of data points per year. It is also one of only a couple in the world that conducts HTS campaigns running assays in parallel. Useful new chemical entities will be generated and tested with an efficiency level of the highest standard", said Francesco Colotta, VP of Oncology , NervianoMS.
"Collaboration with NervianoMS, a leader in area of oncology-focused drug discovery and development, further expands our capabilities to elaborate and accomplish custom synthesis projects to fulfill all requirements of our partners. Our alliance with Nerviano has already produced very promising results and we expect it to strengthen our competitive position," said Alexander Kiselyov, Executive VP of Research & Development, ChemDiv.
Watchlist
This is where you can add this news to your personal favourites
ChemDiv, Inc. announced that it has earned the successful milestone in its Lead Discovery collaboration with Nerviano Medical Sciences (NMS). In October 2007, ChemDiv and NMS expanded their partnership to discover and develop potential anticancer agents. Under the terms of the collaboration ... more
ChemDiv Inc. and Avineuro Pharmaceuticals Inc. have extended the term of their research and development collaboration including formulation, safety and early clinical development studies in areas of neurodegenerative and psychiatric disorders. R&D services will be provided by Chemical Diver ... more
Oncalis AG (Oncalis), a privately-owned Swiss biotechnology company, and ChemDiv Inc. (ChemDiv), a privately-owned,California-based discovery services company announced that they entered into an exclusive agreement for a license to Oncalis a family of PI3K inhibitors. ONC-201, the first dev ... more
ChemDiv, Inc. announced that it has earned the successful milestone in its Lead Discovery collaboration with Nerviano Medical Sciences (NMS). In October 2007, ChemDiv and NMS expanded their partnership to discover and develop potential anticancer agents. Under the terms of the collaboration ... more
ChemDiv, Inc. and Nerviano Medical Sciences (NervianoMS), Milano, Italy, announced an extension of their collaboration to an additional 2 year program. NervianoMS will use services of ChemDiv for building and enriching its portfolio of proprietary discovery chemical libraries. Such compound ... more